This inventor holds 4 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Tg Therapeutics, Inc., Rhizen Pharmaceuticals Sa. Active years: 2017-2023.
Location History:
- New York, NY (US) (2017 - 2021)
- Stuart, FL (US) (2023)
Company Filing History:
4 out of 97 
4 out of 7 
2 out of 51 
Years Active: 2017-2023
Title: Innovations by Peter Sportelli in Antibody Research
Introduction
Peter Sportelli is a prominent inventor based in New York, NY, recognized for his significant contributions to the field of biotechnology, particularly in the development of antibody compositions. With a record of 4 patents, Sportelli has demonstrated a strong commitment to advancing medical treatments for B-cell proliferative disorders.
Latest Patents
Among Sportelli's latest innovations is the development of "Anti-CD20 antibody compositions," which details populations of anti-CD20 antibody proteins with specific ranges of post-translational modifications. This invention also encompasses methods for using and creating these populations, offering promising avenues for medical science. Another noteworthy patent involves the "Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders." This patent presents methods for inhibiting the proliferation of B-cell populations through a combination of agents, which includes at least one P13K-delta selective inhibitor, at least one anti-CD20 antibody, and at least one Bruton's tyrosine kinase (BTK) inhibitor. The methods outlined aim to treat various B-cell hematological malignancies and include kits for implementing these innovative treatments.
Career Highlights
Throughout his career, Peter Sportelli has made significant strides within the biotechnology sector. He has held positions at prominent companies such as Tg Therapeutics, Inc. and Laboratoire Français Du Fractionnement Et Des Biotechnologies. His work at these institutions has allowed him to collaborate with leading professionals and drive forward innovative research.
Collaborations
Peter Sportelli has collaborated with noteworthy colleagues Michael S. Weiss and Hari P. Miskin. These collaborations have facilitated the exchange of ideas and the advancement of their shared goals in antibody research and treatments.
Conclusion
Peter Sportelli's contributions to antibody innovation reflect a dedicated pursuit of better treatments for B-cell proliferative disorders. His work, supported by his recent patents and collaborations, positions him as an influential player in the biotechnology arena, paving the way for future developments in this critical area of medical science.